BackRegeneRx Biopharmaceuticals Overview

RegeneRx Biopharmaceuticals Net Tangible Assets

RegeneRx Biopharmaceuticals's net tangible assets is $0.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$0.00
100.00% YoYΔ $3.14M vs prior year quarter

Peer average

Loading

RegeneRx Biopharmaceuticals Net Tangible Assets History

Loading

RegeneRx Biopharmaceuticals vs. peers: Net Tangible Assets Comparison

Loading

RegeneRx Biopharmaceuticals Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

RegeneRx Biopharmaceuticals (RGRX) FAQ

RegeneRx Biopharmaceuticals (RGRX) currently reports a net tangible assets of $0 as of September 2023. That compares with $-3.1M in the prior-year period — up 100.0% year over year. Use the charts on this page to explore RegeneRx Biopharmaceuticals's net tangible assets history and peer comparisons.

RegeneRx Biopharmaceuticals's net tangible assets increased from $-3.1M to $0 — a 100.0% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

RegeneRx Biopharmaceuticals reported $0 in net tangible assets as of September 2023. That compares with $-3.1M in the prior-year period — up 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for RegeneRx Biopharmaceuticals, and consider following RGRX for alerts when major investors trade the stock.

RegeneRx Biopharmaceuticals is classified in the Healthcare sector. On net tangible assets, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RGRX with unrelated industries.